Evidence map›Paper›PMID 36337005›Full record

ArticleScandinavian journal of medicine & science in sports2023

Short and mid-term characteristics of COVID-19 disease course in athletes: A high-volume, single-center study.

Vencel Juhász, Liliána Szabó, Attila Pavlik, András Tállay, Dorottya Balla, Orsolya Kiss, Máté Babity, Nóra Sydó, Emese Csulak, András Benczúr and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Scandinavian journal of medicine & science in sports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Vencel JuhászHeart and Vascular Center, Semmelweis University, Budapest, Hungary.ORCID https://orcid.org/0000-0001-9100-4952
Liliána SzabóHeart and Vascular Center, Semmelweis University, Budapest, Hungary.ORCID https://orcid.org/0000-0002-4699-3648
Attila PavlikDepartment of Sports Medicine, Semmelweis University, Budapest, Hungary.
András TállayDepartment of Sports Medicine, Semmelweis University, Budapest, Hungary.
Dorottya BallaHeart and Vascular Center, Semmelweis University, Budapest, Hungary.
Orsolya KissHeart and Vascular Center, Semmelweis University, Budapest, Hungary.
Máté BabityHeart and Vascular Center, Semmelweis University, Budapest, Hungary.ORCID https://orcid.org/0000-0001-5334-5430
Nóra SydóHeart and Vascular Center, Semmelweis University, Budapest, Hungary.
Emese CsulakHeart and Vascular Center, Semmelweis University, Budapest, Hungary.
András BenczúrInstitute for Computer Science and Control, Budapest, Hungary.
Anna OrszághInstitute for Computer Science and Control, Budapest, Hungary.
Zsófia GregorHeart and Vascular Center, Semmelweis University, Budapest, Hungary.
Dávid BeckerHeart and Vascular Center, Semmelweis University, Budapest, Hungary.
Béla MerkelyHeart and Vascular Center, Semmelweis University, Budapest, Hungary.
Hajnalka VágóHeart and Vascular Center, Semmelweis University, Budapest, Hungary.ORCID https://orcid.org/0000-0002-3568-3572
Semmelweis University · HUInstitute for Computer Science and Control · HU

Funding

European Union RRF-2.3.1-21-2022-00004Ministry for Innovation and Technology in Hungary, Thematic Excellence Programme 2020-4.1.1.-TKP2020National Research, Development, and Innovation Fund of Hungary NVKP_16-1-2016-0017National Research, Development and Innovation Office of Hungary 2020-1.1.6-JÖVŐ-2021-00013
6 · The paper itself

Abstract

introductionAt the pandemic's beginning, significant concern has risen about the prevalence of myocardial involvement after SARS-CoV-2 infection. We assessed the cardiovascular burden of SARS-CoV-2 in a large cohort of athletes and identified factors that might affect the disease course. We included 633 athletes in our study on whom we performed extensive cardiology examinations after recovering from SARS-CoV-2 infection. More than half of the athletes (n = 322) returned for a follow-up examination median of 107 days after the commencement of their infection.

resultsTroponin T positivity was as low as 1.4% of the athletes, where the subsequently performed examinations did not show definitive, ongoing myocardial injury. Altogether, 31% of the athletes' rapid training rebuild was hindered by persistent or reoccurring symptoms. Female athletes reported a higher prevalence of return to play (RTP) symptoms than their male counterparts (34% vs. 19%, p = 0.005). The development of long COVID symptoms was independently predicted by increasing age and acute symptoms' severity in a multiple regression model (AUC 0.75, CI 0.685-0.801). Athletes presenting with either or both cough and ferritin levels higher than >150 μg/L had a 4.1x (CI 1.78-9.6, p = 0.001) higher odds ratio of developing persistent symptoms.

conclusionWhile SARS-CoV-2 rarely affects the myocardium in athletes, about one in three of them experience symptoms beyond the acute phase. Identifying those athletes with a predisposition to developing long-standing symptoms may aid clinicians and trainers in finding the optimal return-to-play timing and training load rebuild pace.

Indexed as

COVID-19AthletesFemaleHumansMaleMyocardiumPost-Acute COVID-19 SyndromeSARS-CoV-2athletesCOVID-19long COVIDpost-acute COVID syndromereturn to playSARS-CoV-2 infection

Identifiers

PMID36337005
PMCPMC9877648
OpenAlexW4308370956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.